Cereno Scientific (OMX: CRNO-B)

Last close As at 05/08/2026

SEK4.76

−0.02 (−0.33%)

Market capitalisation

SEK1,484m

Based in Sweden, Cereno Scientific is focused on the development of innovative, effective and safe treatments for people with rare cardiovascular and pulmonary diseases. Lead asset CS1, an HDAC inhibitor that acts as an epigenetic modulator, is currently being investigated in a Phase II clinical trial for the treatment of PAH.

Latest Insights

View More

Healthcare | Flash

Cereno Scientific — A step closer to Phase IIb for CS014

Healthcare | podcast

Bull, Bear & Beyond – Cereno Scientific: executive interview

Healthcare | edison tv

Cereno Scientific – executive interview

Market Data

Share Price SEK4.76
Market Cap SEK1,484m
52-Week High SEK11.10
52-Week Low SEK4.30
% Change 1M (4.9)
% Change 6M (30.2)
% Change 12M (49.8)
Ave. Daily Volume 1yr 726,629

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Eva Jagenheim

    CFO

  • Jeppe Øvlesen

    Chairman

  • Sten Sörensen

    CEO

Share Price Chart

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.